期刊文献+

贝伐单抗靶向治疗结直肠癌的临床研究进展 被引量:1

下载PDF
导出
摘要 分子靶向治疗已成为结直肠癌治疗的有效策略。最近,血管生成抑制疗法日益成熟,针对血管内皮生长因子(VEGF)的重组人源化单克隆抗体贝伐单抗(bevacizumab,商品名:Avastin,阿瓦斯丁^TM)成为结直肠癌治疗研究的热点。美国食品药品管理局(FDA)于2004年批准贝伐单抗为晚期结直肠癌的一线用药,
出处 《胃肠病学》 2007年第5期305-307,共3页 Chinese Journal of Gastroenterology
  • 相关文献

参考文献22

  • 1Gerber HP,Ferrara N.The role of VEGF in normal and neoplastic hematopoiesis.J Mol Med,2003,81 (1):20-31.
  • 2Lee JC,Chow NH,Wang ST,et al.Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients.Eur J Cancer,2000,36 (6):748-753.
  • 3Choi HJ,Hyun MS,Jung GJ,et al.Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence.Oncology,1998,55 (6):575-581.
  • 4Warren RS,Yuan H,Matli MR,et al.Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.J Clin Invest,1995,95 (4):1789-1797.
  • 5de Castro Junior G,Puglisi F,de Azambuja E,et al.Angiogenesis and cancer:A cross-talk between basic science and clinical trials (the "do ut des" paradigm).Crit Rev Oncol Hematol,2006,59 (1):40-50.
  • 6Jain RK.Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy.Science,2005,307 (5706):58-62.
  • 7Wang Y,Fei D,Vanderlaan M,et al.Biological activity of bevacizumab,a humanized anti-VEGF antibody in vitro.Angiogenesis,2004,7 (4):335-345.
  • 8封宇飞,雷静,傅得兴.血管内皮生长因子抑制剂——贝伐单抗[J].中国药学杂志,2005,40(19):1519-1520. 被引量:10
  • 9Kabbinavar F,Hurwitz HI,Fehrenbacher L,et al.Phase Ⅱ,randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.J Clin Oncol,2003,21 (1):60-65.
  • 10Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer.N Engl J Med,2004,350 (23):2335-2342.

二级参考文献10

  • 1Zondor SD, Medina PJ.Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies [ J ] . Ann Pharmacoth,2004, 38(7-8): 1258.
  • 2Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy[ J]. Oncologist, 2004, 9(Suppl 1): 2.
  • 3Hsei VC, Novotny WF, Margolin K, et al.Population pharmacokinetic (PK) analysis of bevacizumab(BV) in cancer subjects(abstract)[J].Proc Am Soc Clin Oncol, 2001, 20: 69a.
  • 4Gorden MS, Margolin K, Talpaz M, et al.Phase Ⅰ safety and pharmacokintic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer[J]. J Clin Oncol, 2001, 19:843.
  • 5FDA, AVASTINTM[DB/OL], http:/www.fda, gov/cder/foi/label/2004/12/1250581bl .pdf, 2004-08-11
  • 6Hurwitz H, Fehrenbacher L, Novotny W, et al.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J] .N Engl J Med ,2004 , 350(23):2335.
  • 7Kabbinavar F, Hurwitz HI, Fehrenbacher L, etal, Phase Ⅱ, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin(LV) with FU/LV alone in patients with metastatic colorectal cancer[J]. J Clin Oncol , 2003, 21(1):60.
  • 8Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phaseⅡ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer [ J ] . J Clin Oncol ,2004, 22(11):2184.
  • 9Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias:therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab [ J ]. Clin Cancer Res, 2004, 10 ( 11 ):3577.
  • 10Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer[ J ] . N Engl J Me, 2003, 349 (5): 427.

共引文献9

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部